Attorney General Bridget Hill announced a settlement with Sanofi-Aventis U.S. LLC (Sanofi), which guarantees that Wyoming ...

The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of ...

Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In ...

AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...

The state of Texas is accusing major pharmacy benefit managers and drug companies of colluding to raise the cost of insulin.

French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.